Home  >  News
International
+ Font Resize -

Pfizer's tofacitinib NDA action date extended by US FDA for three months

New York
Thursday, August 23, 2012, 09:00 Hrs  [IST]

The US Food and Drug Administration (FDA) has extended the action date by three months for Pfizer's New Drug Application (NDA) for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA).

The company says, if approved, tofacitinib would be the first RA treatment in a new class of medicines known as Janus kinase (JAK) inhibitors and the first new oral disease-modifying anti-rheumatic drug (or DMARD) for RA in more than 10 years.

The FDA determined that additional data analyses recently submitted by Pfizer constitute a major amendment to the application and will require additional time to review. The FDA has not asked that Pfizer complete any new studies. The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) date of November 21, 2012.

“RA patients are in need of additional treatment options to help fight this serious chronic inflammatory autoimmune disease,” said Dr Yvonne Greenstreet, senior vice president and head of the Medicines Development Group for Pfizer Specialty Care. “We believe that the results from the comprehensive multi-study clinical development program for tofacitinib have demonstrated a favourable benefit-risk profile, and we remain committed to working expeditiously with the FDA to make tofacitinib available to patients.”

Pfizer continues to progress the applications for tofacitinib for the treatment of moderately to severely active RA in markets outside the United States, including Europe and Japan.

Tofacitinib has one of the largest clinical databases of any RA drug ever submitted to the FDA for review. The medication has been evaluated in a comprehensive, multi-study, global clinical development program that included approximately 5,000 patients who represented a broad cross-section of the RA patient population in 44 countries.

Rheumatoid arthritis is a chronic inflammatory autoimmune disease that typically affects the hands and feet, although any joint lined by a synovial membrane may be affected.

Tofacitinib is a novel, oral JAK inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Unlike recent therapies for RA, which are directed at extracellular targets such as pro-inflammatory cytokines, tofacitinib takes a novel approach targeting the intracellular pathways that operate as hubs in the inflammatory cytokine network.

Pfizer strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |